dapsone
FDA Approved
Description
Dapsone is a sulfone antibiotic with anti-inflammatory properties used primarily for dermatological conditions. It is the first-line treatment for dermatitis herpetiformis, a chronic autoimmune blistering skin condition associated with celiac disease. The drug works by inhibiting neutrophil function and reducing inflammatory responses in the skin.
Indications & Therapeutic Use
dermatitis herpetiformis, leprosy, Pneumocystis jirovecii pneumonia prophylaxis
Linked Diseases:
dermatitis herpetiformis
D003874
Global Availability (8 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — |
Available Through
This drug is available for procurement through the following fulfilment partner.
Fulfilment Partner
dapsone
| Generic Name | dapsone |
| Brands | 1 brand available |
| Active Ingredient | dapsone |
| Drug Class | dermatitis herpetiformis |
| Manufacturer | Allergan |
| Dosage Forms | oral tablet 25mg, 50mg, 100mg; topical gel 5%, 7.5% |
| Medical Code | D10AF01 |
| Orphan Status | No |
| Cold Chain | Not Required |
| Lead Time | 7 days |
| Reg. Status | FDA Approved |
| Countries | 8 countries |
Authority Signals
Last Verified3/21/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations9 Validated Nodes